Compare VNET & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNET | CLDX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2011 | 1995 |
| Metric | VNET | CLDX |
|---|---|---|
| Price | $9.08 | $31.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $12.60 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 4.9M | 671.5K |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | $20.06 | $111.39 |
| Revenue Next Year | $21.04 | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $5.15 | $18.56 |
| 52 Week High | $14.48 | $35.83 |
| Indicator | VNET | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 46.09 |
| Support Level | $8.30 | $31.65 |
| Resistance Level | $9.51 | $35.18 |
| Average True Range (ATR) | 0.41 | 1.53 |
| MACD | 0.09 | -0.25 |
| Stochastic Oscillator | 66.12 | 11.48 |
VNET started as AsiaCloud in 1999 and moved into the data center business, opening its first self-developed data center in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of September 2025, it had 52,288 retail cabinets, with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 783 MW of wholesale capacity in service, with a further 306 MW under construction and a further 705 MW held for future development.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.